Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

Unlearn.AI Announces Results Generated from First-of-its-Kind Machine Learning Platform to Accelerate Alzheimer's Drug Development


Unlearn.AI, developer of the first machine-learning (ML) platform that creates Digital Twins to populate Intelligent Control Arms in clinical studies, today presented results generated from the company's latest Alzheimer's disease model at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego. The results presented during a late-breaking session demonstrated that the company's platform can provide digital patient records designed to supplement actual control patients in Alzheimer's disease clinical trials.

"We are excited by the results we presented today as they further validate our platform and its potential to significantly decrease the time spent running clinical trials in an area of significant patient need like Alzheimer's disease," said Charles K. Fisher, Ph.D., founder and CEO of Unlearn.AI. "Drug development in Alzheimer's disease is increasingly expensive and time consuming. We believe that our platform can help alleviate these burdens and accelerate clinical trials to help get new medicines to the patients who need them."

Unlearn is addressing patient recruitment, one of the biggest challenges associated with Alzheimer's disease clinical trials, through its machine learning-based model that incorporates Digital Twins into Intelligent Control Arms of clinical studies. A Digital Twin is a comprehensive, longitudinal and computationally generated clinical record that describes what would have happened if a specific patient had received a placebo. The proprietary DiGenesistm process leverages historical clinical trial datasets from thousands of patients, disease-specific machine learning models and rigorous statistical analysis to create digital records that are perfectly matched to patients in the investigational-treatment arm of studies.

To obtain a large and diverse sample of control data for its Alzheimer's disease model, Unlearn utilized records through its membership with Critical Path for Alzheimer's Disease (CPAD) from 5,000 people with early to moderate Alzheimer's disease from the control arms of 16 historical clinical trials. The model captured the relationship between 50 clinical variables relevant to Alzheimer's disease, such as components of neurologic exams, over 18 months to track the progression of the disease.

"The current state of clinical trials is challenging, especially for debilitating diseases like Alzheimer's where patient recruitment is especially difficult," said Marina Brodsky, Ph.D., former vice president, therapeutic area head, pain and neuroscience, medical affairs at Pfizer. "I am encouraged by these findings and see strong potential in the Unlearn platform to change the way we populate control arms for clinical trials, dramatically reducing time to bring them sooner to patients who desperately need them.''

Details on the effectiveness of Unlearn's earlier Alzheimer's disease model have also been published in Nature Scientific Reports in an article titled Machine learning for comprehensive forecasting of Alzheimer's disease progression.

About the DiGenesistm process

Unlearn is developing machine learning-based tools to address clinical trial challenges by incorporating Digital Twins into Intelligent Control Arms through its proprietary DiGenesistm process. By leveraging historical clinical trial datasets, machine learning models specific for each disease state and rigorous statistical analysis, Unlearn creates Digital Twins that are perfectly matched to treatment patients.

About Unlearn.AI

Unlearn has developed the first machine learning (ML) platform for creating Intelligent Control Arms with Digital Twins through its proprietary DiGenesistm process, allowing drug developers to dramatically reduce therapy development time, while lowering the risk of trial failure, thereby increasing confidence in clinical trial results. Unlearn is working closely with biopharmaceutical and medical device companies as well as regulators to ensure its methods meet the highest scientific and regulatory standards. Visit https://www.unlearn.ai or follow @UnlearnAI on Twitter, @unlearn-ai on LinkedIn.


These press releases may also interest you

at 08:25
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") today announced its second quarter 2020 financial results for the period ended June 30, 2020. "We are pleased by recent news releases from both Ipsen Pharmaceuticals and Elevation...

at 08:07
"Scientists, physicians and public health experts continue to learn about COVID-19 and how it is spread. We must use the limited tools we have today to slow the spread of the COVID-19 virus and minimize the damage it causes to individuals, our...

at 08:05
Pfizer Inc. today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead's investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of...

at 08:05
Bruker Corporation today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.04 per share on the Company's common stock. The dividend will be paid on September 18, 2020 to stockholders of...

at 08:05
Senseonics Holdings, Inc. , a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced Highmark Inc. will begin...

at 08:05
Aimmune Therapeutics, Inc. , a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at...



News published on 7 december 2019 at 21:05 and distributed by: